

A location-scale joint model for studying the link between the time-dependent subject-specific variability of blood pressure and competing events

Léonie Courcoul^{1*}, Christophe Tzourio¹, Mark Woodward^{2,3},
Antoine Barbieri¹, and H el ene Jacqmin-Gadda¹

¹Univ. Bordeaux, INSERM, Bordeaux Population Health, U1219, France

²The George Institute for Global Health, Imperial College London, UK

³The George Institute for Global Health, University of New South Wales, Sydney, Australia

R esum e

Given the high incidence of cardio and cerebrovascular diseases (CVD), and its association with morbidity and mortality, its prevention is a major public health issue. A high level of blood pressure is a well-known risk factor for these events and an increasing number of studies suggest that blood pressure variability may also be an independent risk factor. However, these studies suffer from significant methodological weaknesses. In this work we propose a new location-scale joint model for the repeated measures of a marker and competing events. This joint model combines a mixed model including a subject-specific and time-dependent residual variance modeled through random effects, and cause-specific proportional intensity models for the competing events. The risk of events may depend simultaneously on the current value of the variance, as well as, the current value and the current slope of the marker trajectory. The model is estimated by maximizing the likelihood function using the Marquardt-Levenberg algorithm. The estimation procedure is implemented in an R-package and is validated through a simulation study. This model is applied to study the association between blood pressure variability and the risk of CVD and death from other causes. Using data from a large clinical trial on the secondary prevention of stroke, we find that the current individual variability of blood pressure is associated with the risk of CVD and death. Moreover, the comparison with a model without heterogeneous variance shows the importance of taking into account this variability in the goodness-of-fit and for dynamic predictions.

Keywords : Blood Pressure, Competing events, Heterogeneous variance, Joint model, Location-scale model, Cardio and cerebrovascular diseases.

1 Introduction

Cardiovascular diseases, such as ischaemic heart disease, and cerebrovascular events are two leading causes of death. Moreover these diseases lead often to acquired physical disability or to dementia. In addition, medical care and disability management following this type of disease generate significant societal, human, and financial distress [de Pourville, 2016]. Given the frequency of cardio and cerebrovascular diseases (CVD) and its dramatic consequences at the individual and societal level, the identification of modifiable risk factors is essential to implement prevention programs. Hypertension (high values of blood pressure) is a long-known major risk factor for these diseases. The prevalence of hypertension is high, increases with age, and effective blood pressure-lowering treatments are available. More recently, the visit-to-visit variability of blood pressure has been shown to be associated with an increased risk of stroke and cardiovascular events independently of the level of blood pressure in several studies [Pringle et al., 2003, Rothwell et al., 2010, Shimbo et al., 2012].

Most of the previous studies have used the individual empirical standard deviation, or some other measure of variation (e.g. the coefficient of variation) or extreme value (e.g. the maximum), of blood pressure as an explanatory variable in a Cox model for the event risk. However, they were exposed to methodological issues. A first strategy consists of calculating the empirical standard deviation of blood pressure on all available measurements [Mehlum et al., 2018]. This strategy induces conditioning on the future, likely leading to bias because measurements after the current time (and sometimes after the event time) are used to predict the event at the current time [Andersen and Keiding, 2012, de Courson et al., 2021]. A second strategy consists of computing the standard deviation of blood pressure on the measurements collected over an initial period of the study, keeping in the sample only the

individuals who did not have the event before the end of this period in order to predict the risk beyond this period [de Courson et al., 2021]. This could induce selection bias and certainly creates loss of power. To avoid these issues, the standard deviation of blood pressure can be considered as a time-dependent variable and calculated using only measurements before the event. Nevertheless, this approach neglects the measurement error of the standard deviation, which is a serious issue when the number of measurements differs between individuals, and requires imputation of the standard deviation at all event times. These limitations may introduce bias [Prentice, 1982]. Moreover, blood pressure and its standard deviation are endogenous variables, and the Cox model is not adapted to this type of variable [Commenges and Jacqmin-Gadda, 2015]. Finally, it is essential to account for competing death from other causes because mortality and CVD risk both increases with age and may be both associated with blood pressure.

Joint models allow simultaneous analysis of longitudinal data and clinical events. They combine a mixed model for repeated measures of exposure and a time-to-event model. Functions of the random effects from the mixed model are included as explanatory variables in the time-to-event model to account for the association between the two outcomes. This allows evaluation of the impact of the longitudinal data on the event risk without bias, contrary to the two stage estimation [Rizopoulos, 2012, Tsiatis and Davidian, 2004, Henderson et al., 2000].

Location-scale mixed models have been introduced to investigate the heterogeneity of intra-subject variability for longitudinal data by introducing random effects in the variance modelling [Hedeker and Nordgren, 1999]. For studying the association between the variability of a biomarker and a clinical event, Gao et al.[Gao et al., 2011] and Barrett et al.[Barrett et al., 2019] have proposed a joint model combining a mixed model including a subject-specific random effect for the residual variance and a proportional hazard model for the event risk. However, the considered dependence structure is quite restrictive since, in their models, the event risk depends only on the random effects and not on time-dependent characteristics of the marker trajectory, such as the current value or the current slope. In addition, none of them assumes for time-dependent subject-specific variability of the marker and they do not handle competing events.

The objective of our work was, therefore, to propose a new location-scale joint model accounting for both time-dependent individual variability of a marker and competing events. To do this, we extended the model proposed by Gao et al.[Gao et al., 2011] and Barrett et al.[Barrett et al., 2019] to include a time-dependent variability, competing events, a more flexible dependence structure between the event and the marker trajectory, and more flexible baseline risk functions. In contrast to the previous works we propose a frequentist estimation approach which is implemented in the R-package `FlexVarJM`.

This paper is organized as follows. Section 2 describes the model and the estimation procedure using a robust algorithm for maximizing the likelihood. Section 3 presents a simulation study to assess the estimation procedure performance. In section 4, the model is applied to the data from the Perindopril Protection Against Stroke Study (PROGRESS) clinical trial, a blood-pressure lowering trial for the secondary prevention of stroke [Mac Mahon et al., 2001]. Finally, Section 5 concludes this work with some elements of discussion.

2 Method

Let us consider a sample of N individuals. For each individual $i \in \{1, \dots, N\}$, we consider the n_i -vector of repeated measures $Y_i = (Y_{i1}, \dots, Y_{in_i})^\top$ with Y_{ij} the value of the longitudinal outcome of individual i at time t_{ij} ($j = 1, \dots, n_i$). Assuming two competing events, we denote $T_i = \min(T_{i1}^*, T_{i2}^*, C_i)$ the observed time with T_{ik}^* the real time for the event k ($k = 1, 2$) and C_i the censoring time for the i th individual. Censoring event and real time are supposed to be independent. We then denote $\delta_i \in \{0, 1, 2\}$ the individual event indicator such as $\delta_i = k$ if the competing event $k \in \{1, 2\}$ occurs and $\delta_i = 0$ otherwise.

2.1 Joint model with time-dependent individual variability

We propose joint modelling for a longitudinal outcome and competing events using a shared random-effect approach. The longitudinal submodel is defined by a linear mixed-effect model with heterogeneous variance :

$$\begin{cases} Y_{ij} = Y_i(t_{ij}) = \tilde{Y}_i(t_{ij}) + \epsilon_{ij} = X_{ij}^\top \beta + Z_{ij}^\top b_i + \epsilon_i(t_{ij}), \\ \epsilon_{ij}(t_{ij}) \sim \mathcal{N}(0, \sigma_i^2(t_{ij})) \quad \text{with} \quad \log(\sigma_i(t_{ij})) = O_{ij}^\top \mu + M_{ij}^\top \tau_i \end{cases} \quad (1)$$

with X_{ij} , O_{ij} , Z_{ij} and M_{ij} four vectors of explanatory variables for subject i at visit j , respectively associated with the fixed-effect vectors β and μ , and the subject-specific random-effect vector b_i and τ_i , such as

$$\begin{pmatrix} b_i \\ \tau_i \end{pmatrix} \sim \mathcal{N} \left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \begin{pmatrix} \Sigma_b & \Sigma_{\tau b} \\ \Sigma_{\tau b}^\top & \Sigma_\tau \end{pmatrix} \right)$$

The risk function for the event $k \in \{1, 2\}$ is defined by :

$$\lambda_{ik}(t) = \lambda_{0k}(t) \exp \left(W_i^\top \gamma_k + \alpha_{1k} \tilde{y}_i(t) + \alpha_{2k} \tilde{y}'_i(t) + \alpha_{\sigma k} \sigma_i(t) \right), \quad (2)$$

with $\lambda_{0k}(t)$ the baseline risk function, W_i a vector of baseline covariates associated with the regression coefficient γ_k , and α_{1k} , α_{2k} and $\alpha_{\sigma k}$ the regression coefficients associated with the current value $\tilde{y}_i(t)$, the current slope $\tilde{y}'_i(t)$ and the current variability $\sigma_i(t)$ of the marker, respectively. Different parametric forms for the baseline risk function can be considered, such as exponential, Weibull, or, for more flexibility, a B-splines base with Q knots defined by :

$$\log(\lambda_{0k}(t)) = \exp \left(\sum_{q=1}^{Q+4} \eta_{qk} B_q(t, \nu_k) \right),$$

where $B_q(t, \nu_k)$ is the q -th basis function of B-splines with the knot vector ν_k and η_{qk} is the associated parameter to be estimated.

2.2 Estimation procedure

Let θ be the set of parameters to be estimated including parameters of the Cholesky decomposition of the covariance matrix of the random effects, β , μ , $\alpha^\top = (\alpha_{11}, \alpha_{21}, \alpha_{\sigma 1}, \alpha_{12}, \alpha_{22}, \alpha_{\sigma 2})$, $\gamma^\top = (\gamma_1, \gamma_2)$ and the parameters of the two baseline risk functions. Considering the frequentist approach, the parameter estimation is obtained by maximizing the likelihood function. The contribution of individual i to the marginal likelihood is defined by :

$$\begin{aligned} \mathcal{L}_i(\theta; Y_i, T_i, \delta_i) &= \int p(Y_i, T_i, \delta_i | b_i, \tau_i; \theta) f(b_i, \tau_i; \theta) db_i d\tau_i \\ &= \int f(Y_i | b_i, \tau_i; \theta) \exp \left(- \sum_{k=1}^2 \Lambda_{ik}(T_i | b_i, \tau_i; \theta) \right) \prod_{k=1}^2 \lambda_{ik}(T_i | b_i, \tau_i; \theta)^{\mathbb{1}_{\delta_i=k}} f(b_i, \tau_i; \theta) db_i d\tau_i, \end{aligned}$$

with $f(b_i, \tau_i; \theta)$ a multivariate Gaussian density and $f(Y_i | b_i, \tau_i; \theta) = \prod_{j=1}^{n_i} f(Y_{ij} | b_i, \tau_i; \theta)$ where $f(Y_{ij} | b_i, \tau_i; \theta)$ is a univariate Gaussian density. For $k \in \{1, 2\}$, $\Lambda_{ik}(T_i | b_i, \tau_i; \theta)$ is the cumulative risk function given by :

$$\Lambda_{ik}(t | b_i, \tau_i; \theta) = \int_0^t \lambda_{ik}(u | b_i, \tau_i; \theta) du \quad (3)$$

In cohort studies, data are frequently left-truncated. Left-truncation arises as soon as the time scale is not the time since inclusion and the subjects are enrolled only if they are free of the event at inclusion [Betensky and M, 2015]. This is the case in most studies where the time-scale is age. To deal with left-truncation (also called delayed entry), the individual contribution to the likelihood must be divided by the probability to be free of any event at entry time T_{0i} :

$$\mathcal{L}_i^{DE}(\theta; Y_i, T_i, \delta_i) = \frac{\mathcal{L}_i(\theta; Y_i, T_i, \delta_i)}{\int \exp(-\Lambda_{i1}(T_{0i} | b_i, \tau_i; \theta) - \Lambda_{i2}(T_{0i} | b_i, \tau_i; \theta)) f(b_i, \tau_i; \theta) db_i d\tau_i}$$

Because the integral on the random effects does not have an analytical solution, the integral is computed by a Quasi Monte Carlo (QMC) approximation [Pan and Thompson, 2007], using deterministic quasi-random sequences. The approximation of the integral is defined by :

$$\mathcal{L}_i(\theta; Y_i, T_i, \delta_i) \simeq \frac{1}{S} \sum_{s=1}^S p(Y_i, T_i, \delta_i | b_i^s, \tau_i^s; \theta)$$

with (b_i^1, \dots, b_i^S) and $(\tau_i^1, \dots, \tau_i^S)$ are draws of a S -sample in the sobol sequel for the distribution $f(b_i, \tau_i; \theta)$.

To approximate the cumulative risk function given in equation (3), we use the Gauss-Kronrod quadrature approximation with 15 points [Gonnet, 2012].

Parameter estimation is obtained by maximizing the log-likelihood function $\ell(\theta; Y_i, T_i, \delta_i) = \log \left(\prod_{i=1}^N \mathcal{L}_i(\theta; Y_i, T_i, \delta_i) \right)$. The maximization is performed using the `marqLevAlg` R-package based on the Marquardt-Levenberg algorithm [Phillips et al., 2021]. The latter is a robust variant of the Newton-Raphson algorithm [Levenberg, 1944, Marquardt,

1963] which iteratively updates the parameters θ to be estimated until convergence with the following formula at iteration $l + 1$:

$$\theta^{(l+1)} = \theta^{(l)} - \psi_l (\tilde{H}(\theta^{(l)}))^{-1} \nabla(\ell(\theta^{(l)}))$$

where $\theta^{(l)}$ is the set of parameters at iteration l , $\nabla(\ell(\theta^{(l)}))$ the gradient of the log-likelihood at iteration l and $\tilde{H}(\theta^{(l)})$ the inflated Hessian matrix where the diagonal terms of the Hessian matrix $H(\theta^{(l)})$ are replaced by :

$$\tilde{H}(\theta^{(l)})_{ii} = H(\theta^{(l)})_{ii} + \phi_l \left[(1 - \rho_l) |H(\theta^{(l)})_{ii}| + \rho_l \text{tr}(H(\theta^{(l)})) \right].$$

The scalars ψ_l , ϕ_l and ρ_l are internally determined at each iteration l to ensure that $\tilde{H}(\theta^{(l)})$ be definite-positive, $\tilde{H}(\theta^{(l)})$ approaches $H(\theta^{(l)})$ when θ approaches $\hat{\theta}$ and insure improvement of the likelihood at each iteration. Stringent convergence criteria are used, relying on parameter and function stability, and the relative distance to the maximum computed from the first and second derivatives of the log-likelihood which must not exceed a threshold ε_d : $\frac{\nabla(\ell(\theta^{(l)}))(H(\theta^{(l)}))^{-1} \nabla(\ell(\theta^{(l)}))}{m} < \varepsilon_d$, with m the number of parameters. This algorithm was previously compared to other algorithms (EM, BFGS and L-BFGS-B) and the results showed that this algorithm was the most reliable [Philipps et al., 2021].

The variances of the estimates are estimated by computing the inverse of the Hessian matrix computed by finite differences. The variances of the estimated parameters from the covariance matrix of the random effects are computed using the Delta-Method [Meyer et al., 2013].

To limit computation time and insure precise estimates of parameters and their standard error, we propose a two-step estimation procedure. In the first step, we applied the Marquardt-algorithm with a small number $S1$ of QMC draws (e.g. $S1 = 500$) until convergence is achieved. In the second step, we consider a number $S2 > S1$ of QMC draws (e.g. $S2 = 5000$) to improve the accuracy of the computation of the standard error of the estimates that requires numerical derivation. If the Hessian matrix is not invertible, a few additional iterations are performed until invertibility is achieved. The selection of the number of QMC draws $S1$ and $S2$ significantly impacts computation time. Therefore, for a model selection step, we recommend that users compare various models based on results obtained in step 1 (using likelihood or information criteria) with a small value for $S1$. It is advisable to perform step 2, which involves a larger number of QMC draws, exclusively for the final model selected.

We implemented the computation of individual probability of having event k between time s and $s + t$ given that the subject i did not experience any event before time s , its trajectory of marker until time s , $\mathcal{Y}_i(s)$, and the set of estimated parameters. The prediction is defined for subject i by :

$$\begin{aligned} \pi_i(s, t; \hat{\theta}) &= P(s < T_i < s + t, \delta_i = k | T_i > s, \mathcal{Y}_i(s), \hat{\theta}) \\ &= \frac{\int \left[\int_s^{s+t} \exp(-\sum_{c=1}^2 \Lambda_{ic}(u|b_i, \tau_i, \hat{\theta})) \lambda_{ik}(u|b_i, \tau_i, \hat{\theta}) du \right] f(\mathcal{Y}_i(s)|b_i, \tau_i, \hat{\theta}) f(b_i, \tau_i|\hat{\theta}) db_i d\tau_i}{\int \exp(-\sum_{c=1}^2 \Lambda_{ic}(s|b_i, \tau_i, \hat{\theta})) f(\mathcal{Y}_i(s)|b_i, \tau_i, \hat{\theta}) f(b_i, \tau_i|\hat{\theta}) db_i d\tau_i} \end{aligned} \quad (4)$$

As previously, the integral over the random effect is computed by QMC approximation and the integral over time with the Gauss-Kronrod quadrature.

The corresponding 95% confidence interval of predictions is obtained by the following Monte Carlo algorithm. For L large enough and $l = 1, \dots, L$ ($L = 1000$ for instance) :

- Generate $\hat{\theta}^{(l)} \sim \mathcal{N}(\hat{\theta}, V(\hat{\theta}))$ where $V(\hat{\theta})$ is given by the inverse of the Hessian matrix at $\hat{\theta}$
- Compute $\tilde{\pi}_i^{(l)}(s, t; \hat{\theta}^{(l)})$ from equation (4)
- Compute the 95% confidence interval from the 2.5th and 97.5th percentiles of the L-sample of $\tilde{\pi}_i^{(l)}(s, t; \hat{\theta}^{(l)})$

2.3 Software

The R-package `FlexVarJM` has been developed for the estimation of the model, the prediction of the subject-specific random effects, and the computation of the individual predicted probabilities of events. The package allows estimation of a model with an unconstrained time-trend for the marker trajectory, one or two events

with exponential, Weibull or B-splines baseline risk functions, and a flexible dependence structure between the events and the marker (possibly including the current value, the current slope and the subject-specific time-dependent variability). The development version of `FlexVarJM` is available on Github at the following link : <https://github.com/LeonieCourcoul/FlexVarJM> and the fixed version can be installed from CRAN [Courcoul et al., 2023].

3 Simulations

In order to evaluate the performance of the estimation procedure, we performed a simulation study using a design similar to the application data.

3.1 Design of simulations

Visit times were generated using a uniform distribution centered around each specified time, with a variation of approximately one month in either direction. For each visit time, one measurement of the marker was generated, using a linear mixed-effects model with fixed and random intercept and slope, and heterogeneous variance :

$$\begin{cases} Y(t_{ij}) = \beta_0 + b_{0i} + (\beta_1 + b_{1i}) \times t_{ij} + \epsilon_i(t_{ij}) \\ \epsilon_i(t_{ij}) \sim \mathcal{N}(0, \sigma_i^2(t_{ij})) \quad \text{with} \quad \log(\sigma_i(t_{ij})) = \mu_0 + \tau_{0i} + (\mu_1 + \tau_{1i}) \times t_{ij} \end{cases} \quad (5)$$

with $b_i = (b_{0i}, b_{1i})^\top$ and $\tau_i = (\tau_{0i}, \tau_{1i})^\top$. Competing event times T_{ik}^* ($k = 1, 2$) were generated using the Brent's univariate root-finding method [Brent, 1973] according to the following proportional hazards models :

$$\lambda_{ik}(t) = \lambda_{0k}(t) \exp(\alpha_{1k} \tilde{y}_i(t) + \alpha_{2k} \tilde{y}'_i(t) + \alpha_{\sigma k} \sigma_i(t)) \quad (6)$$

with $\lambda_{0k}(t) = \kappa_k t^{\kappa_k - 1} e^{\zeta_{0k}}$ being a Weibull function. Individuals were censored at C_i the last visit observed in the dataset. Finally, the observed time was defined by $T_i = \min(T_{i1}^*, T_{i2}^*, C_i)$. Measures of the marker Y posterior to T_i were removed from the datasets.

Five scenarii were considered varying the number of repeated measures and the correlation structure between the random effects :

- Scenario A : a maximum of 7 times of measurement, at 0-year, 0.5 year and then one per year until 5 years ; with random effects b_i independent of τ_i .
- Scenario B : a maximum of 13 times of measurements, at 0 year, every 3 months the first year and then twice per year until 5 years (mimicking PROGRESS) ; with random effects b_i independent of τ_i .
- Scenario C : same time points as in Scenario A ; with correlated random effects.
- Scenario D : same time points as in Scenario B ; with correlated random effects.
- Scenario E (Misspecified model) : marker generated with a quadratic trend but estimated with a linear trend ; one event ; same time points as in Scenario B ; with random effects b_i independent of τ_i .

For each scenario, 300 datasets of 500 and 1000 subjects were generated. Parameter values for data generation are indicated in the tables of results. The models were estimated with the estimation procedure presented in Section 2.2, given $S1 = 500$ and $S2 = 5000$ draws for the QMC integration approximation.

3.2 Results

Tables 1, 2 and 3 report the mean estimates, the empirical and mean asymptotic standard error of the estimated parameters and the coverage rate of their 95% confidence intervals for scenario A, B and C on 500 individuals. Results for scenario D and for larger sample size are in the Supporting Information (tables S1 to S5). The estimation procedure provided satisfactory results for the four sets of simulations. Indeed, the bias was minimal, the mean asymptotic and the empirical standard errors were close, and the coverage rates of the 95% confidence interval were close to the nominal value. We only observed slight under coverage of the confidence interval for some parameters in the covariance matrix of the random effects that tend to reduce for larger sample size (N=1000 subjects, see Tables S1, S2 and S3 in Supporting Information). We can note that the bias is minimal from the first step but the second step helps to reduce the difference between the mean asymptotic and the empirical standard deviations and thus improve the coverage rates. This simulation study also illustrates the impact of the choice of $S1$ and $S2$ on the computation time : for scenario A, the medians of computation time are around 13 minutes (25 iterations in median) and 9 minutes (1 iteration in median) respectively for step 1 and 2. Finally, Scenario E was performed

TABLE 1 – Simulation results for scenario A with 500 subjects (7 measures, b_i and τ_i independent).*

Parameter			Step 1				Step 2			
	True value		Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)
<i>Longitudinal submodel</i>										
<i>Intercept</i>	β_0	142	142.1	0.736	0.717	94.31	142.1	0.730	0.728	94.98
<i>Slope</i>	β_1	3	2.943	0.288	0.253	89.97	2.945	0.280	0.271	92.64
<i>Variability</i>	μ_0	2.4	2.396	0.027	0.026	94.65	2.395	0.027	0.027	95.32
	μ_1	0.05	0.050	0.017	0.015	92.98	0.051	0.016	0.016	94.31
Σ_b	$\sigma_{b_0}^2$	207.36	205.0	17.31	16.17	91.97	205.1	17.19	16.60	91.97
	$\sigma_{b_0b_1}$	-17.28	-16.06	4.132	3.663	87.96	-16.04	3.936	4.020	92.64
	$\sigma_{b_1}^2$	9.224	9.351	1.673	1.308	84.95	9.279	1.536	1.465	91.64
Σ_τ	$\sigma_{\tau_0}^2$	0.0001	0.004	0.006	0.006	98.66	0.004	0.007	0.006	98.33
	$\sigma_{\tau_0\tau_1}$	-0.0006	-0.002	0.005	0.005	92.64	-0.003	0.005	0.006	95.99
	$\sigma_{\tau_1}^2$	0.0157	0.016	0.005	0.004	91.97	0.017	0.005	0.005	93.31
<i>Survival submodel 1</i>										
<i>Current variance</i>	$\alpha_{\sigma 1}$	0.07	0.064	0.041	0.039	94.65	0.064	0.041	0.039	95.32
<i>Current value</i>	α_{11}	0.02	0.020	0.008	0.007	95.65	0.020	0.008	0.007	95.32
<i>Current slope</i>	α_{21}	0.01	0.008	0.072	0.066	94.31	0.007	0.071	0.067	95.99
<i>Weibull</i>	$\sqrt{\kappa_1}$	1.1	1.099	0.056	0.059	97.66	1.098	0.056	0.059	97.99
	ζ_{01}	-7	-6.884	1.257	1.199	94.31	-6.885	1.257	1.204	94.65
<i>Survival submodel 2</i>										
<i>Current variance</i>	$\alpha_{\sigma 2}$	0.15	0.169	0.091	0.046	92.31	1.678	0.091	0.054	96.32
<i>Current value</i>	α_{12}	-0.01	-0.012	0.014	0.009	96.32	-0.012	0.015	0.010	96.66
<i>Current slope</i>	α_{22}	-0.14	-0.171	0.173	0.086	92.64	-0.167	0.170	0.095	94.65
<i>Weibull</i>	$\sqrt{\kappa_2}$	1.3	1.310	0.102	0.079	96.99	1.311	0.105	0.084	97.99
	ζ_{02}	-4	-4.075	1.389	1.366	95.99	-4.075	1.388	1.401	95.65

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 299 replicates with complete convergence over 300.

to evaluate the impact of a misspecified marker trajectory (quadratic versus linear time trend). As expected, the estimates of the fixed effects and covariance matrix for b_i in the mixed models are biased, but the estimates of the model for the residual variance and of the time-to-event model are robust (Table S6 in Supporting Information).

4 Application

4.1 PROGRESS clinical trial

We estimated the proposed model on the data from the PROGRESS clinical trial [Mac Mahon et al., 2001] a blood-pressure lowering, multicentre, double-blind randomized placebo-controlled clinical trial including patients with a history of stroke or transient ischaemic attack within 5 years before inclusion. Patients were recruited between May 1995 and November 1997. The follow-up comprised five visits in the first year, then two visits each year until the end of the study or the occurrence of a major CVD (stroke, myocardial infarction and cerebral hemorrhage) or death. At each visit, blood pressure was measured twice and we analysed the mean of the two measurements at each time. Prior to randomization, eligible patients were subjected to a 4-week run-in phase to test their tolerance to the treatment. At randomization, patients assigned to the control group stopped the treatment. In order to avoid an effect of the change of therapy at randomization, we removed the blood pressure measure at randomization. Finally, the current study was conducted over 3710 Non Asian patients, 1856 for the controlled group and 1854 for the treatment group, and included 672 CVD and 150 deaths without CVD. There are 2525 (68%) men and 1185 (32%) women. The average age at entry in the study is 67 years old (sd = 9.8) with a minimum at 26 and a maximum at 91 years old.

4.2 Specification of the model

This study aimed to evaluate the impact of the blood pressure variability on the risk of CVD and death from other causes. To do so, we estimated the proposed joint model (Model CVCS+V, for current value, current slope and variance) with heterogeneous time-dependent variance defined by (1) and (2) using the time since the first considered blood pressure measurement. The trajectory of blood pressure was described over time by a linear mixed effect model. The individual time trend of the marker and the variance were modelled by a linear trend. The baseline hazard functions of both events were defined by B-splines with three knots placed at the quantiles of the observed events. According to the AIC, the model with three knots was better than models with 1 or 5 knots for each baseline

TABLE 2 – Simulation results for scenario B with 500 subjects (13 measures, b_i and τ_i independent).*

Parameter		Step 1				Step 2				
	True value	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	
Longitudinal submodel										
<i>Intercept</i>	β_0	142	142.0	0.779	0.655	90.67	142.0	0.767	0.721	92.67
<i>Slope</i>	β_1	3	2.996	0.252	0.201	90.00	3.000	0.248	0.235	93.33
<i>Variability</i>	μ_0	2.4	2.402	0.019	0.018	92.00	2.401	0.019	0.018	92.67
	μ_1	0.05	0.047	0.012	0.011	92.00	0.049	0.012	0.012	94.00
Σ_b	$\sigma_{b_0}^2$	207.36	208.1	17.79	14.18	87.00	208.0	17.29	15.92	92.33
	$\sigma_{b_0 b_1}$	-17.28	-15.74	4.165	2.954	77.00	-15.85	4.022	3.614	85.00
	$\sigma_{b_1}^2$	9.224	9.236	1.476	0.948	79.00	9.256	1.322	1.246	89.67
Σ_τ	$\sigma_{\tau_0}^2$	0.0001	0.002	0.003	0.002	97.33	0.002	0.003	0.003	97.67
	$\sigma_{\tau_0 \tau_1}$	-0.0006	-0.001	0.003	0.003	91.33	-0.001	0.003	0.004	93.67
	$\sigma_{\tau_1}^2$	0.0157	0.015	0.003	0.003	88.67	0.016	0.003	0.003	94.67
Survival submodel 1										
<i>Current variance</i>	$\alpha_{\sigma 1}$	0.07	0.063	0.030	0.028	92.67	0.065	0.029	0.028	93.67
<i>Current value</i>	α_{11}	0.02	0.020	0.006	0.007	96.33	0.020	0.006	0.007	96.33
<i>Current slope</i>	α_{21}	0.01	0.007	0.057	0.053	96.33	0.007	0.055	0.055	96.00
<i>Weibull</i>	$\sqrt{K_1}$	1.1	1.106	0.055	0.054	94.00	1.105	0.055	0.055	95.00
	ζ_{01}	-7	-6.912	0.992	1.042	95.67	-6.914	0.992	1.050	95.67
Survival submodel 2										
<i>Current variance</i>	$\alpha_{\sigma 2}$	0.15	0.158	0.034	0.030	92.67	0.159	0.031	0.032	97.33
<i>Current value</i>	α_{12}	-0.01	-0.010	0.008	0.008	94.67	-0.010	0.008	0.008	95.33
<i>Current slope</i>	α_{22}	-0.14	-0.146	0.064	0.061	94.00	-0.145	0.063	0.064	95.00
<i>Weibull</i>	$\sqrt{K_2}$	1.3	1.299	0.067	0.067	95.67	1.299	0.066	0.068	96.33
	ζ_{02}	-4	-4.104	1.173	1.111	93.67	-4.107	1.173	1.139	93.67

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 300 replicates with complete convergence over 300.

TABLE 3 – Simulation results for scenario C with 500 subjects (7 measures, b_i and τ_i correlated).*

Parameter		Step 1				Step 2				
	True value	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	
Longitudinal submodel										
<i>Intercept</i>	β_0	142	141.9	0.833	0.742	92.28	141.9	0.820	0.756	93.33
<i>Slope</i>	β_1	3	3.019	0.320	0.282	90.61	3.023	0.314	0.290	92.00
<i>Variability</i>	μ_0	2.4	2.401	0.035	0.033	93.62	2.399	0.035	0.033	94.33
	μ_1	0.05	0.050	0.016	0.015	92.62	0.050	0.016	0.016	93.67
$\Sigma_{b\tau}$	$\sigma_{b_0}^2$	210.25	209.7	20.69	16.90	88.23	209.4	20.39	17.72	91.33
	$\sigma_{b_0 b_1}$	-15.95	-15.43	4.734	3.942	88.59	-15.48	4.398	4.209	92.33
	$\sigma_{b_0 \tau_0}$	2.9	2.796	0.610	0.521	88.93	2.812	0.592	0.533	89.67
	$\sigma_{b_0 \tau_1}$	-0.145	-0.129	0.251	0.210	89.54	-0.115	0.240	0.220	93.00
	$\sigma_{b_1}^2$	9.05	9.181	1.745	1.371	85.91	9.084	1.599	1.479	91.33
	$\sigma_{b_1 \tau_0}$	-0.304	-0.295	0.178	0.157	91.95	-0.291	0.169	0.162	94.67
	$\sigma_{b_1 \tau_1}$	0.067	0.069	0.073	0.061	88.93	0.065	0.068	0.063	92.00
	$\sigma_{\tau_0}^2$	0.1309	0.123	0.029	0.026	87.53	0.128	0.029	0.028	91.67
	$\sigma_{\tau_0 \tau_1}$	-0.0206	-0.019	0.011	0.008	87.53	-0.021	0.010	0.010	94.00
	$\sigma_{\tau_1}^2$	0.0141	0.014	0.005	0.004	80.87	0.015	0.005	0.005	94.33
Survival submodel 1										
<i>Current variance</i>	$\alpha_{\sigma 1}$	0.07	0.065	0.051	0.046	93.29	0.067	0.050	0.047	94.67
<i>Current value</i>	α_{11}	0.02	0.021	0.012	0.011	93.29	0.021	0.012	0.011	93.33
<i>Current slope</i>	α_{21}	0.01	-0.004	0.077	0.076	93.62	-0.051	0.817	0.470	94.00
<i>Weibull</i>	$\sqrt{K_1}$	1.1	1.094	0.052	0.054	96.31	1.095	0.052	0.055	96.67
	ζ_{01}	-7	-7.133	1.437	1.296	93.96	-6.958	3.204	2.612	94.67
Survival submodel 2										
<i>Current variance</i>	$\alpha_{\sigma 2}$	0.15	0.166	0.079	0.051	91.28	0.165	0.077	0.057	95.00
<i>Current value</i>	α_{12}	-0.01	-0.016	0.018	0.013	91.95	-0.012	0.017	0.014	93.67
<i>Current slope</i>	α_{22}	-0.14	-0.154	0.113	0.088	95.64	-0.178	0.486	0.253	95.67
<i>essai</i>	$\sqrt{K_2}$	1.3	1.314	0.078	0.069	94.30	1.314	0.074	0.072	94.67
	ζ_{02}	-4	-4.084	1.758	1.524	94.30	-3.983	2.469	2.109	95.00

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 298 replicates with complete convergence over 300 for step 1 and for 300 replicates with complete convergence over 300 for step 2.

hazard function (respectively 298946.2, 298948.8 and 298951). The model allowed the risk of each event to depend on the time-dependent intra-subject variability, the individual current value and the current slope. The longitudinal submodel and the variance submodel were adjusted for treatment group and survival submodels were adjusted for treatment group, age at baseline and sex (male versus female) :

$$\begin{cases} y(t_{ij}) = \beta_0 + b_{0i} + (\beta_1 + b_{1i}) \times t_{ij} + \beta_2 \times trt_i + \epsilon_i(t_{ij}) \\ \epsilon_i(t_{ij}) \sim \mathcal{N}(0, \sigma_i^2(t_{ij})) \quad \text{with} \quad \log(\sigma_i(t_{ij})) = \mu_0 + \tau_{0i} + (\mu_1 + \tau_{1i}) \times t_{ij} + \mu_2 \times trt_i \\ \lambda_{ik}(t) = \lambda_{0k}(t) \exp(\gamma_{0k}trt_i + \gamma_{1k}male_i + \gamma_{2k}age + \alpha_{1k}\tilde{y}_i(t) + \alpha_{2k}\tilde{y}'_i(t) + \alpha_{\sigma k}\sigma_i(t)) \end{cases}$$

The estimation was performed with $S1 = 500$ and $S2 = 10000$ draws of QMC to ensure a greater accuracy.

This model was compared to two classical joint model without heterogeneous variance , i.e. $\sigma_i^2(t_{ij}) = \sigma^2$ for all $i = 1, \dots, N$ and $j = 1, \dots, n_i$. The first one allowed the risk of each event to depend only on the individual current value (Model CV) and the second one on both the individual current value and current slope (Model CVCS).

4.3 Results

The AIC from the complete model (298946.2) was clearly better than the AIC from the two joint models with a constant residual variance and either with a dependence on the current value only (302062.4) or with a dependence on the current value and the current slope (302011.6), showing the importance of taking into account a time-dependent subject-specific variance.

Table 4 provides estimates from the complete joint model and Table 5 the covariance matrix of the random effects and their standard errors computed through the Delta-Method. Blood pressure was lower for individuals from the treatment group ($\beta_2 = -8.03$, p -value < 0.001). The variance of the residual error was heterogeneous between the subjects ($\widehat{Var}(\tau_{0i}) = 0.13$, $sd = 7e - 3$) and was lower for treated patients ($\hat{\mu}_2 = -0.030$, p -value = 0.028). The risk of CVD events increased with age ($HR = 1.04$ for one year, $IC = [1.03; 1.05]$) and was higher for men ($HR = 1.34$, $IC = [1.13; 1.60]$). Adjusting for age, sex and treatment group, the risk of CVD was associated with the current blood pressure variance ($HR = 1.07$, $IC = [1.03; 1.10]$) : the higher the standard error of blood pressure, the higher the risk of CVD ; and with the current slope of blood pressure ($HR = 0.86$, $IC = [0.82; 0.90]$). This last result means that patients with a decreasing slope had a higher risk of CVD. These patients could be those with an history of hypertension. A similar effect is observed on the CVCS model (see Table S7 in Supporting Information). However, this risk did not depend on the current blood pressure value ($HR = 0.99$, $IC = [0.986; 1.002]$). The risk of death from other causes was higher for older individuals ($HR = 1.05$, $IC = [1.03; 1.07]$) and for men ($HR = 1.69$, $IC = [1.16; 2.48]$). It was not associated with the treatment group. Moreover, it was associated with the current value of blood pressure : the instantaneous risk of death was multiplied by 0.90 ($IC = [0.816; 0.993]$) for each increase of 5 mmHg of the mean blood pressure. The risk of death was also associated with the current blood pressure variance ($HR = 1.13$, $IC = [1.05; 1.21]$) and with the current slope ($HR = 0.89$, $IC = [0.798; 0.998]$).

4.4 Goodness-of-fit assessment

To assess the fit of the time-to-event submodels, we computed for each event, the predicted cumulative hazard function at each event time by plugging the empirical Bayes estimates of the random effects in the formula for the risk function. Then we compared the mean of this predicted cumulative hazard function with its Nelson-Aalen estimator for the whole sample (Figure S1 of the Supporting Information) and stratified according to sex and randomization group (Figure S2). These figures show that the joint model adequately fitted both risks and that the proportional risk assumption was valid for each categorical variable.

To highlight the impact of adding a subject-specific and time-dependent residual variance in the mixed model, we computed the individual predictions of the marker over time for some selected subjects. The predicted value of blood pressure corresponds to the conditional expectation given the random effects, defined by $\hat{E}(Y_i(t)|\tilde{b}_i, \tilde{\tau}_i)$ and the prediction interval around this predicted values is given by $\hat{E}(Y_i(t)|\tilde{b}_i, \tilde{\tau}_i) \pm 1.96\hat{V}(Y_i(t)|\tilde{b}_i, \tilde{\tau}_i)$. For each subject the empirical Bayes estimates of the random effects, denoted by $(\tilde{b}_i, \tilde{\tau}_i) = \operatorname{argmax} f(b_i, \tau_i|Y_i, T_i, \delta_i)$, corresponds to the mode of their estimated conditional posterior given the data. They are computed by maximising $f(Y_i, T_i, \delta_i)f(b_i, \tau_i)$

TABLE 4 – Parameter estimates of the joint model on the Progress clinical trial data (CVCS+V model).

Parameter	Estimate	Standard error	p-value
<i>Survival submodel for CVD</i>			
BP current variance	0.064	0.017	< 0.001
BP current value	-0.006	0.004	0.160
BP current slope	-0.152	0.022	< 0.001
treatment group	-0.153	0.085	0.073
male	0.296	0.089	< 0.001
age	0.038	0.005	< 0.001
<i>Survival submodel for Death</i>			
BP current variance	0.120	0.035	< 0.001
BP current value	-0.021	0.010	0.030
BP current slope	-0.114	0.057	0.045
treatment group	-0.117	0.171	0.493
male	0.527	0.194	0.006
age	0.051	0.010	< 0.001
<i>Longitudinal submodel</i>			
<u>Blood Pressure Mean</u>			
intercept	142.5	0.330	< 0.001
time	-0.104	0.072	0.150
treatment group	-8.029	0.441	< 0.001
<u>Blood Pressure Residual Variance</u>			
intercept	2.341	0.012	< 0.001
time	0.007	0.004	0.086
treatment group	-0.030	0.014	0.028

BP : Blood Pressure

TABLE 5 – Covariance matrix (and standard errors) of the random effects computed using the Delta-Method.

$$\begin{aligned}
 \Sigma &= \begin{bmatrix}
 Var(b_{0i}) & & & & \\
 Cov(b_{0i}, b_{1i}) & Var(b_{1i}) & & & \\
 Cov(b_{0i}, \tau_{0i}) & Cov(b_{1i}, \tau_{0i}) & Var(\tau_{0i}) & & \\
 Cov(b_{0i}, \tau_{1i}) & Cov(b_{1i}, \tau_{1i}) & Cov(\tau_{0i}, \tau_{1i}) & Var(\tau_{1i}) & \\
 & & & &
 \end{bmatrix} \\
 &= \begin{bmatrix}
 212.3_{(5.6)} & & & & \\
 -19.0_{(1.2)} & 8.6_{(0.4)} & & & \\
 2.2_{(0.15)} & -0.29_{(0.04)} & 0.13_{(7e-3)} & & \\
 -0.18_{(0.06)} & 0.16_{(0.02)} & -0.02_{(3e-3)} & 0.012_{(1e-3)} &
 \end{bmatrix}
 \end{aligned}$$

with the Marquardt-Levenberg algorithm.

For some selected subjects still at risk at 3 years, Figure 1 presents the predicted values and their confidence intervals from the models with and without subject-specific residual variance (CVCS+V and CVCS). It shows that assuming a time-dependent and subject-specific residual variability allows a better fit of the uncertainty around the individual prediction.

4.5 Predictions

We compared the predictive abilities of models with and without time-dependent individual variability using AUC in a 5-fold cross-validation. The individual predictions of having CVD (or death) between 3 and 5 years for subjects free of any event at 3 years were computed using equation (4). The AUC was computed using the `timeROC` package [Blanche et al., 2015]. The results are slightly better for the model with heterogeneous variability. We




FIGURE 1 – Prediction over time of the individual blood pressure and its prediction interval at 95% for 6 subjects. Model CVCS+V assumed a time-dependent subject-specific variability and the model CVCS assumes a homogeneous and constant variability. The black triangles are the observed measurements.

obtained respectively 0.609 (0.067) and 0.576 (0.067) for the risk of CVD, and 0.637 (0.078) and 0.616 (0.079) for the risk of death.

To illustrate the effect of taking into account the current value of individual variance, we also computed the predicted risk of the events between 3 and 5 years for different subjects from both models, with and without time-dependent individual variability. We used the subjects selected for Figure 1 and present their predictions obtained via the cross-validation procedure. Figures 2 and 3 shows that, for both the risk of CVD and the risk of death, the prediction is higher with the complete model when the individual experienced the event between 3 and 5 years than with the model without the heterogeneous variability. More, the predicted risk is smaller with the complete model when the individual do not experience the corresponding event.

5 Discussion

In this work, we have proposed a new joint model with a subject-specific time-dependent variance that extends the models proposed by Gao et al. [Gao et al., 2011] and Barrett et al. [Barrett et al., 2019]. Indeed, this new model allows time and covariate dependent individual variance and a flexible dependence structure between the competing events and the longitudinal marker. In particular, the risk of events may depend on both the current value and the current slope of the marker, in addition to the subject-specific time-dependent standard deviation of the residual error. This is an important asset of the model given that, in most health research contexts, it is more




FIGURE 2 – Prediction of the risk of CVD between 3 and 5 years (with its 95% confidence interval indicated by dashed lines), for six patients at risk at 3 years, for Model CVCS+V (purple) and Model CVCS (orange). The dashed lines represent the observed time.

sensible to assume that the event risk depends on the time-dependent current value or slope of the marker instead of only time-independent random effects. Moreover, accounting for competing events may be important in many clinical applications. Simulation study allows us to demonstrate the good performance of the estimation procedure and to study the impact of the choice of S_1 and S_2 . The model converged without bias and with good coverage rates, whatever the number of individual and the number of visits. Moreover, the estimates of the time-to-event sub-model are quite robust to a misspecification of the marker trajectory. In addition, we provided an R-package that allows frequentist estimation with a robust estimation algorithm which had shown very good behaviour in our simulations and in a previous work with different models [Philipps et al., 2021].

The analysis of the PROGRESS trial has shown that a high variability of blood pressure is associated with a high risk of CVD and death from other causes. Moreover, the individual residual variability depends on treatment group. These results are difficult to generalise to the entire population as the population study considered in this clinical trial is for the secondary prevention of stroke.

In this work, we have supposed that the visit times were not informative and that missing measurements before




FIGURE 3 – Prediction of the risk of Death between 3 and 5 years (with its 95% confidence interval indicated by dashed lines), for six patients at risk at 3 years, for Model CVCS+V (purple) and Model CVCS (orange). The dashed lines represent the observed time.

the event were missing at random. In the PROGRESS clinical study, these hypotheses are quite plausible since visits were planned following a pre-specified protocol and the rate of missed visits before the event was low (less than 3%). For application to observational studies, it could be useful to extend this approach to consider an informative observation process. However, such a model would require three submodels : a mixed model for the evolution of the marker, a submodel for repeated events to describe the visit process and a model for the competing events of interest. This model would rely on non-verifiable parametric assumptions and its estimation process would be much more cumbersome.

The proposed approach addressed both right censoring and left-truncation, the two most common observation schemes for time-to-event data. Considering interval censoring and semi-competing events could represent a valuable enhancement. This extension would be useful when the exact time of onset of the main event is unknown (dementia for instance) and the competing event may arise after the main event (death). However, this would necessitate modeling the three transition intensities and the interval censoring would significantly complicate the computation of the likelihood.

Such joint models with dependence on the heterogeneous variance (that can be viewed as an extension of the location-scale mixed model [Hedeker and Nordgren, 1999]) are of great interest to investigate the association between the variability of markers or risk factors and the risk of health events in various fields of medical research, possibly allowing to improve the prediction ability for the event. For instance, hypotheses have emerged about the link between emotional instability and the risk of psychiatric events, or the variability of glycemia and the prognosis of diabetes. Thanks to wearable devices, recent medical research studies often include frequent repeated measures of exposures or biomarkers, allowing the investigation of hypotheses regarding the variability.

Acknowledgments

Computer time for this article was provided by the computing facilities MCIA of the Université de Bordeaux and of the Université de Pau et des Pays de l'Adour.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This work was funded by the French National Research Agency (grant ANR-21-CE36 for the project "Joint Models for Epidemiology and Clinical research").

This PhD program is supported within the framework of the PIA3 (Investment for the Future). Project reference : 17-EURE-0019.

Références

- G. de Pourville. Coût de la prise en charge des accidents vasculaires cérébraux en France. *Archives of Cardiovascular Diseases Supplements*, 8(2) :161–168, February 2016. ISSN 1878-6480. doi : 10.1016/S1878-6480(16)30330-5.
- Edward Pringle, Charles Phillips, Lutgarde Thijs, Christopher Davidson, Jan A. Staessen, Peter W. de Leeuw, Matti Jaaskivi, Choudomir Nachev, Gianfranco Parati, Eoin T. O'Brien, Jaakko Tuomilehto, John Webster, Christopher J. Bulpitt, Robert H. Fagard, and on behalf of the Syst-Eur Investigators. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. *Journal of Hypertension*, 21(12) :2251–2257, December 2003. ISSN 0263-6352.
- Peter M Rothwell, Sally C Howard, Eamon Dolan, Eoin O'Brien, Joanna E Dobson, Bjorn Dahlöf, Peter S Sever, and Neil R Poulter. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *The Lancet*, 375(9718) :895–905, March 2010. ISSN 0140-6736. doi : 10.1016/S0140-6736(10)60308-X.
- Daichi Shimbo, Jonathan D. Newman, Aaron K. Aragaki, Michael J. LaMonte, Anthony A. Bavry, Matthew Allison, JoAnn E. Manson, and Sylvia Wassertheil-Smoller. Association Between Annual Visit-to-Visit Blood Pressure Variability and Stroke in Postmenopausal Women. *Hypertension*, 60(3) :625–630, September 2012. doi : 10.1161/HYPERTENSIONAHA.112.193094. Publisher : American Heart Association.
- Maria H Mehlum, Knut Liestøl, Sverre E Kjeldsen, Stevo Julius, Tsushung A Hua, Peter M Rothwell, Giuseppe Mancina, Gianfranco Parati, Michael A Weber, and Eivind Berge. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. *European Heart Journal*, 39(24) :2243–2251, June 2018. ISSN 0195-668X. doi : 10.1093/eurheartj/ehx760.
- Per Kragh Andersen and Niels Keiding. Interpretability and importance of functionals in competing risks and multistate models. *Statistics in Medicine*, 31(11-12) :1074–1088, 2012. ISSN 1097-0258. doi : 10.1002/sim.4385.

- Hugues de Courson, Loïc Ferrer, Antoine Barbieri, Phillip J. Tully, Mark Woodward, John Chalmers, Christophe Tzourio, and Karen Leffondré. Impact of Model Choice When Studying the Relationship Between Blood Pressure Variability and Risk of Stroke Recurrence. *Hypertension*, 78(5) :1520–1526, November 2021. ISSN 0194-911X, 1524-4563. doi : 10.1161/HYPERTENSIONAHA.120.16807.
- R. L. Prentice. Covariate measurement errors and parameter estimation in a failure time regression model. *Biometrika*, 69(2) :331–342, August 1982. ISSN 0006-3444. doi : 10.1093/biomet/69.2.331.
- Daniel Commenges and Helene Jacqmin-Gadda. *Dynamical Biostatistical Models*. CRC Press, October 2015. ISBN 978-1-4987-2968-0.
- Dimitris Rizopoulos. *Joint Models for Longitudinal and Time-to-Event Data : With Applications in R*. CRC Press, June 2012. ISBN 978-1-4398-7286-4.
- Anastasios A. Tsiatis and Marie Davidian. Joint modeling of longitudinal and time-to-event data : an overview. *Statistica Sinica*, 14(3) :809–834, 2004. ISSN 1017-0405.
- Robin Henderson, Peter Diggle, and Angela Dobson. Joint modelling of longitudinal measurements and event time data. *Biostatistics*, 1(4) :465–480, December 2000. ISSN 1465-4644. doi : 10.1093/biostatistics/1.4.465.
- D Hedeker and R Nordgren. Mixregls : A program for mixed-effects location scale analysis. *Journal of Statistical Software*, 52(12) :1–38, March 1999. doi : 10.18637/jss.v052.i12.
- Feng Gao, J. Philip Miller, Chengjie Xiong, Julia A. Beiser, Mae Gordon, and The Ocular Hypertension Treatment Study (OHTS) Group. A joint-modeling approach to assess the impact of biomarker variability on the risk of developing clinical outcome. *Statistical Methods & Applications*, 20(1) :83–100, March 2011. ISSN 1613-981X. doi : 10.1007/s10260-010-0150-z.
- Jessica K. Barrett, Raphael Huille, Richard Parker, Yuichiro Yano, and Michael Griswold. Estimating the association between blood pressure variability and cardiovascular disease : An application using the ARIC Study. *Statistics in Medicine*, 38(10) :1855–1868, 2019. ISSN 1097-0258. doi : 10.1002/sim.8074.
- S. Mac Mahon, S. Neal, C Tzourio, A. Rodgers, M. Woodward, J Cutler, C Anderson, and J Chalmers. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *The Lancet*, 358(9287) :1033–1041, September 2001. ISSN 0140-6736. doi : 10.1016/S0140-6736(01)06178-5.
- RA Betensky and Mandel M. Recognizing the problem of delayed entry in time-to-event studies : Better late than never for clinical neuroscientists. *Ann Neurol.*, 78(6) :839–44, 2015. doi : 10.1002/ana.24538.
- Jianxin Pan and Robin Thompson. Quasi-Monte Carlo estimation in generalized linear mixed models. *Computational Statistics & Data Analysis*, 51(12) :5765–5775, August 2007. ISSN 01679473. doi : 10.1016/j.csda.2006.10.003.
- Pedro Gonnet. A Review of Error Estimation in Adaptive Quadrature. *ACM Computing Surveys*, 44(4) :22 :1–22 :36, August 2012. ISSN 03600300. doi : 10.1145/2333112.2333117.
- Viviane Philipps, Boris P. Hejblum, Mélanie Prague, Daniel Commenges, and Cécile Proust-Lima. Robust and Efficient Optimization Using a Marquardt-Levenberg Algorithm with R Package marqLevAlg. *The R Journal*, 13 :273, 2021. ISSN 2073-4859. doi : 10.32614/RJ-2021-089.
- Kenneth Levenberg. A method for the solution of certain non-linear problems in least squares. *Quarterly of Applied Mathematics*, 2(2) :164–168, 1944. ISSN 0033-569X, 1552-4485. doi : 10.1090/qam/10666.
- Donald W. Marquardt. An Algorithm for Least-Squares Estimation of Nonlinear Parameters. *Journal of the Society for Industrial and Applied Mathematics*, 11(2) :431–441, June 1963. ISSN 0368-4245. doi : 10.1137/0111030.
- Karin Meyer, David Houle, et al. Sampling based approximation of confidence intervals for functions of genetic covariance matrices. In *Proc. Assoc. Advmt. Anim. Breed. Genet*, volume 20, pages 523–526, 2013.
- Léonie Courcoul, Antoine Barbieri, and Hélène Jacqmin-Gadda. *FlexVarJM : Estimate Joint Models with Subject-Specific Variance*, 2023. URL <https://CRAN.R-project.org/package=FlexVarJM>. R package version 0.1.0.

R. P. Brent. *Algorithms for minimization without derivatives*. Englewood Cliffs ; [Hemel Hempstead] : Prentice-Hall, 1973. ISBN 978-0-13-022335-7.

Paul Blanche, Cécile Proust-Lima, Lucie Loubère, Claudine Berr, Jean-François Dartigues, and Hélène Jacqmin-Gadda. Quantifying and comparing dynamic predictive accuracy of joint models for longitudinal marker and time-to-event in presence of censoring and competing risks. *Biometrics*, 71(1) :102–113, 2015. ISSN 1541-0420. doi : 10.1111/biom.12232.

Supplementary Material

A location-scale joint model for studying the link between the time-dependent subject-specific variability of blood pressure and competing events

Léonie Courcoul^{1*}, Christophe Tzourio¹, Mark Woodward^{2,3},
Antoine Barbieri¹, and H el ene Jacqmin-Gadda¹

¹Univ. Bordeaux, INSERM, Bordeaux Population Health, U1219, France

² The George Institute for Global Health, Imperial College London, UK

³ The George Institute for Global Health, University of New South Wales, Sydney, Australia

TABLE S1 – Simulation results for scenario A with 1000 subjects (7 measures, b_i and τ_i independent).*

Parameter		Step 1				Step 2				
	True value	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	
<i>Longitudinal submodel</i>										
<i>Intercept</i>	β_0	142	142.0	0.533	0.509	94.97	142.0	0.530	0.515	95.33
<i>Slope</i>	β_1	3	2.987	0.189	0.181	94.63	2.985	0.184	0.194	96.33
<i>Variability</i>	μ_0	2.4	2.399	0.019	0.019	94.30	2.398	0.019	0.019	94.00
	μ_1	0.05	0.050	0.012	0.011	91.95	0.050	0.012	0.012	94.67
Σ_b	$\sigma_{b_0}^2$	207.36	205.9	11.68	11.11	94.30	205.9	11.67	11.74	95.67
	$\sigma_{b_0 b_1}$	-17.28	-15.70	3.089	2.658	86.91	-15.76	2.947	2.893	90.33
	$\sigma_{b_1}^2$	9.224	9.096	1.183	0.935	85.91	9.096	1.118	1.058	92.00
Σ_τ	$\sigma_{\tau_0}^2$	0.0001	0.002	0.004	0.003	99.33	0.003	0.005	0.004	97.67
	$\sigma_{\tau_0 \tau_1}$	-0.0006	-0.002	0.003	0.003	95.64	-0.002	0.004	0.004	95.33
	$\sigma_{\tau_1}^2$	0.0157	0.016	0.003	0.003	92.62	0.017	0.004	0.004	95.00
<i>Survival submodel 1</i>										
<i>Current variance</i>	$\alpha_{\sigma 1}$	0.07	0.066	0.028	0.026	94.63	0.067	0.027	0.026	94.67
<i>Current value</i>	α_{11}	0.02	0.020	0.005	0.005	94.63	0.020	0.006	0.005	94.33
<i>Current slope</i>	α_{21}	0.01	0.012	0.045	0.046	95.64	0.011	0.045	0.047	95.00
<i>Weibull</i>	$\sqrt{\kappa_1}$	1.1	1.094	0.042	0.041	93.96	1.094	0.042	0.041	94.33
	ζ_{01}	-7	-6.991	0.837	0.820	95.30	-6.990	0.838	0.825	95.00
<i>Survival submodel 2</i>										
<i>Current variance</i>	$\alpha_{\sigma 2}$	0.15	0.155	0.034	0.029	90.94	0.155	0.033	0.032	94.33
<i>Current value</i>	α_{12}	-0.01	-0.010	0.006	0.006	94.30	-0.010	0.006	0.006	94.33
<i>Current slope</i>	α_{22}	-0.14	-0.143	0.060	0.054	95.97	-0.143	0.058	0.057	96.67
<i>Weibull</i>	$\sqrt{\kappa_2}$	1.3	1.297	0.054	0.053	94.97	1.297	0.054	0.055	96.00
	ζ_{02}	-4	-4.035	0.919	0.897	96.31	-4.035	0.915	0.916	97.67

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 298 replicates with complete convergence over 300 for step 1 and 300 replicates over 300 for step 2.

TABLE S2 – Simulation results for scenario B with 1000 subjects (13 measures, b_i and τ_i independent).*

Parameter		Step 1				Step 2				
		True value	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)
Longitudinal submodel										
Intercept	β_0	142	142.0	0.544	0.476	91.30	142.0	0.539	0.500	93.33
Slope	β_1	3	2.993	0.184	0.149	89.97	2.992	0.174	0.162	93.33
Variability	μ_0	2.4	2.401	0.012	0.013	94.98	2.400	0.012	0.013	95.33
	μ_1	0.05	0.048	0.008	0.008	92.31	0.049	0.008	0.008	93.33
Σ_b	$\sigma_{b_0}^2$	207.4	209.9	12.91	10.44	88.63	209.6	12.61	11.03	90.00
	$\sigma_{b_0 b_1}$	-17.28	-15.75	3.140	2.182	78.60	-15.87	2.915	2.433	84.33
	$\sigma_{b_1}^2$	9.224	9.161	1.083	0.724	78.60	9.147	0.999	0.855	87.67
Σ_τ	$\sigma_{\tau_0}^2$	0.0001	0.001	0.002	0.001	93.65	0.001	0.003	0.002	94.00
	$\sigma_{\tau_0 \tau_1}$	-0.0006	-0.001	0.002	0.002	92.98	-0.001	0.002	0.002	94.00
	$\sigma_{\tau_1}^2$	0.0157	0.015	0.002	0.002	89.97	0.016	0.002	0.0023	93.33
Survival submodel 1										
Current variance	$\alpha_{\sigma 1}$	0.07	0.063	0.020	0.019	92.31	0.064	0.020	0.019	93.67
Current value	α_{11}	0.02	0.020	0.005	0.005	96.32	0.020	0.005	0.005	96.33
Current slope	α_{21}	0.01	0.010	0.041	0.038	91.97	0.009	0.041	0.039	93.67
Weibull	$\sqrt{\kappa_1}$	1.1	1.098	0.036	0.038	95.99	1.097	0.036	0.038	95.67
	ζ_{01}	-7	-6.934	0.703	0.722	96.32	-6.934	0.702	0.724	96.00
Survival submodel 2										
Current variance	$\alpha_{\sigma 2}$	0.15	0.154	0.022	0.020	93.31	0.154	0.021	0.021	95.33
Current value	α_{12}	-0.01	-0.010	0.005	0.005	95.65	-0.010	0.005	0.005	96.00
Current slope	α_{22}	-0.14	-0.149	0.050	0.042	92.98	-0.148	0.044	0.043	97.00
Weibull	$\sqrt{\kappa_2}$	1.3	1.304	0.048	0.047	95.65	1.303	0.048	0.047	95.67
	ζ_{02}	-4	-4.123	0.765	0.776	93.65	-4.124	0.763	0.786	95.00

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 299 replicates with complete convergence over 300 for step 1 and 300 replicates over 300 for step 2.

TABLE S3 – Simulation results for scenario C with 1000 subjects (7 measures, b_i and τ_i correlated).*

Parameter		Step 1				Step 2				
		True value	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)
Longitudinal submodel										
Intercept	β_0	142	141.9	0.564	0.529	93.31	141.9	0.554	0.535	94.00
Slope	β_1	3	3.006	0.215	0.202	93.98	3.002	0.206	0.210	95.67
Variability	μ_0	2.4	2.402	0.024	0.023	93.65	2.400	0.024	0.023	95.33
	μ_1	0.05	0.049	0.012	0.011	93.98	0.050	0.011	0.011	95.33
$\Sigma_{b\tau}$	$\sigma_{b_0}^2$	210.25	211.1	13.86	12.24	90.64	210.7	13.26	12.65	93.33
	$\sigma_{b_0 b_1}$	-15.95	-15.72	3.211	2.904	92.64	-15.87	3.053	2.998	94.67
	$\sigma_{b_0 \tau_0}$	2.9	2.811	0.399	0.369	92.64	2.847	0.386	0.378	93.67
	$\sigma_{b_0 \tau_1}$	-0.145	-0.144	0.175	0.152	90.64	-0.131	0.162	0.155	93.00
	$\sigma_{b_1}^2$	9.05	9.155	1.163	1.019	90.97	9.172	1.065	1.032	95.00
	$\sigma_{b_1 \tau_0}$	-0.304	-0.288	0.120	0.113	90.97	-0.291	0.114	0.117	94.33
	$\sigma_{b_1 \tau_1}$	0.067	0.064	0.051	0.044	90.64	0.061	0.047	0.046	91.33
	$\sigma_{\tau_0}^2$	0.1309	0.123	0.020	0.019	90.64	0.129	0.019	0.019	95.67
	$\sigma_{\tau_0 \tau_1}$	-0.0206	-0.020	0.007	0.006	92.64	-0.020	0.007	0.007	96.67
	$\sigma_{\tau_1}^2$	0.0141	0.014	0.003	0.003	90.64	0.014	0.003	0.003	95.00
Survival submodel 1										
Current variance	$\alpha_{\sigma 1}$	0.07	0.066	0.034	0.032	94.98	0.067	0.033	0.031	94.00
Current value	α_{11}	0.02	0.021	0.008	0.007	92.64	0.021	0.008	0.007	92.67
Current slope	α_{21}	0.01	-0.004	0.055	0.051	93.65	-0.005	0.053	0.054	93.67
Weibull	$\sqrt{\kappa_1}$	1.1	1.092	0.037	0.037	94.98	1.092	0.037	0.039	95.00
	ζ_{01}	-7	-7.123	0.960	0.883	94.31	-7.122	0.959	0.902	94.33
Survival submodel 2										
Current variance	$\alpha_{\sigma 2}$	0.15	0.154	0.034	0.034	94.98	0.154	0.034	0.034	96.67
Current value	α_{12}	-0.01	-0.010	0.009	0.009	95.99	-0.010	0.009	0.009	96.67
Current slope	α_{22}	-0.14	-0.143	0.061	0.056	94.31	-0.141	0.061	0.057	94.67
Weibull	$\sqrt{\kappa_2}$	1.3	1.302	0.047	0.045	94.31	1.303	0.046	0.046	95.67
	ζ_{02}	-4	-4.107	1.003	1.021	96.66	-4.098	1.005	1.052	96.33

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 299 replicates with complete convergence over 300 for step 1 and 300 replicates over 300 for step 2.

TABLE S4 – Simulation results for scenario D with 500 subjects (13 measures, b_i and τ_i correlated).*

Parameter		Step 1				Step 2				
		True value	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)
Longitudinal submodel										
<i>Intercept</i>	β_0	142	141.9	0.825	0.746	91.33	141.9	0.812	0.756	91.64
<i>Slope</i>	β_1	3	2.980	0.327	0.282	89.67	2.993	0.311	0.295	93.65
<i>Variability</i>	μ_0	2.4	2.400	0.034	0.033	93.67	2.398	0.034	0.033	94.65
$\Sigma_{b\tau}$	μ_1	0.05	0.049	0.016	0.015	93.33	0.049	0.016	0.016	93.98
	$\sigma_{b_0}^2$	210.25	210.7	21.02	16.98	88.67	210.5	20.41	17.85	91.97
	$\sigma_{b_0 b_1}$	-15.95	-15.57	4.788	3.991	88.33	-15.70	4.509	4.281	90.97
	$\sigma_{b_0 \tau_0}$	2.9	2.882	0.580	0.525	91.67	2.922	0.554	0.538	94.31
	$\sigma_{b_0 \tau_1}$	-0.145	-0.171	0.235	0.211	93.00	-0.162	0.222	0.222	94.31
	$\sigma_{b_1}^2$	9.05	9.196	1.912	1.412	84.00	9.164	1.664	1.497	91.97
	$\sigma_{b_1 \tau_0}$	-0.304	-0.314	0.180	0.157	91.33	-0.307	0.169	0.162	92.98
	$\sigma_{b_1 \tau_1}$	0.067	0.073	0.072	0.061	90.33	0.069	0.065	0.064	94.65
	$\sigma_{\tau_0}^2$	0.1309	0.124	0.030	0.026	88.00	0.129	0.030	0.027	91.97
	$\sigma_{\tau_0 \tau_1}$	-0.0206	-0.020	0.011	0.009	84.00	-0.020	0.011	0.010	89.97
$\sigma_{\tau_1}^2$	0.0141	0.014	0.006	0.004	82.33	0.014	0.005	0.005	89.63	
Survival submodel 1										
<i>Current variance</i>	$\alpha_{\sigma 1}$	0.07	0.069	0.050	0.046	94.33	0.070	0.049	0.046	94.65
<i>Current value</i>	α_{11}	0.02	0.021	0.011	0.011	92.67	0.021	0.011	0.011	93.31
<i>Current slope</i>	α_{21}	0.01	0.013	0.086	0.076	94.00	0.011	0.082	0.076	95.32
<i>Weibull</i>	$\sqrt{\kappa_1}$	1.1	1.102	0.054	0.054	95.0	1.102	0.054	0.053	94.65
	ζ_{01}	-7	-7.170	1.389	1.289	93.33	-7.178	1.379	1.292	93.98
Survival submodel 2										
<i>Current variance</i>	$\alpha_{\sigma 2}$	0.15	0.184	0.196	0.057	93.0	0.176	0.167	0.063	95.99
<i>Current value</i>	α_{12}	-0.01	-0.017	0.049	0.015	89.67	-0.015	0.041	0.016	93.31
<i>Current slope</i>	α_{22}	-0.14	-0.170	0.238	0.093	96.67	-0.167	0.330	0.104	97.32
<i>Weibull</i>	$\sqrt{\kappa_2}$	1.3	1.326	0.157	0.072	93.00	1.324	0.164	0.075	93.98
	ζ_{02}	-4	-3.697	3.413	1.643	91.00	-3.817	2.702	1.718	92.46

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 300 replicates with complete convergence over 300 for step 1 and 299 replicates over 300 for step 2.

TABLE S5 – Simulation results for scenario D with 1000 subjects (13 measures, b_i and τ_i correlated).*

Parameter		Step 1				Step 2				
		True value	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)
Longitudinal submodel										
<i>Intercept</i>	β_0	142	141.9	0.575	0.532	91.30	141.9	0.557	0.540	93.67
<i>Slope</i>	β_1	3	3.003	0.209	0.202	93.31	3.007	0.197	0.209	95.67
<i>Variability</i>	μ_0	2.4	2.405	0.025	0.023	93.65	2.402	0.025	0.023	94.33
$\Sigma_{b\tau}$	μ_1	0.05	0.049	0.012	0.011	93.31	0.049	0.011	0.011	94.33
	$\sigma_{b_0}^2$	210.3	212.6	14.51	12.35	91.97	212.5	13.32	12.88	94.00
	$\sigma_{b_0 b_1}$	-15.95	-15.61	3.440	2.883	91.30	-15.87	3.064	3.024	94.33
	$\sigma_{b_0 \tau_0}$	2.9	2.856	0.417	0.370	90.97	2.898	0.404	0.382	92.67
	$\sigma_{b_0 \tau_1}$	-0.145	-0.169	0.171	0.150	90.97	-0.151	0.161	0.157	93.67
	$\sigma_{b_1}^2$	9.05	9.061	1.298	1.021	89.97	9.123	1.049	1.066	94.67
	$\sigma_{b_1 \tau_0}$	-0.304	-0.306	0.124	0.112	92.31	-0.304	0.116	0.115	94.33
	$\sigma_{b_1 \tau_1}$	0.067	0.073	0.049	0.043	92.31	0.068	0.045	0.044	95.33
	$\sigma_{\tau_0}^2$	0.1309	0.123	0.021	0.018	90.97	0.130	0.020	0.020	93.33
	$\sigma_{\tau_0 \tau_1}$	-0.0206	-0.019	0.008	0.006	89.63	-0.208	0.007	0.007	94.33
$\sigma_{\tau_1}^2$	0.0141	0.013	0.004	0.003	86.29	0.014	0.003	0.003	95.00	
Survival submodel 1										
<i>Current variance</i>	$\alpha_{\sigma 1}$	0.07	0.063	0.035	0.031	91.30	0.065	0.034	0.031	94.00
<i>Current value</i>	α_{11}	0.02	0.021	0.008	0.007	93.65	0.021	0.008	0.007	94.00
<i>Current slope</i>	α_{21}	0.01	0.014	0.053	0.051	94.31	0.015	0.051	0.050	94.67
<i>Weibull</i>	$\sqrt{\kappa_1}$	1.1	1.099	0.035	0.037	95.32	1.099	0.034	0.037	96.33
	ζ_{01}	-7	-7.087	0.850	0.860	96.66	-7.087	0.853	0.867	96.33
Survival submodel 2										
<i>Current variance</i>	$\alpha_{\sigma 2}$	0.15	0.159	0.042	0.035	92.64	0.159	0.040	0.035	95.00
<i>Current value</i>	α_{12}	-0.01	-0.012	0.011	0.009	94.65	-0.012	0.010	0.009	94.67
<i>Current slope</i>	α_{22}	-0.14	-0.151	0.074	0.060	92.98	-0.150	0.063	0.058	95.67
<i>Weibull</i>	$\sqrt{\kappa_2}$	1.3	1.313	0.046	0.046	94.98	1.313	0.047	0.046	95.00
	ζ_{02}	-4	-3.938	1.160	1.041	94.31	-3.937	1.156	1.054	94.67

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 300 replicates with complete convergence over 300.

TABLE S6 – Simulation results for scenario E with 500 subjects (Misspecified model).*

Parameter		Step 1				Step 2				
		Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	Mean	Empirical SE	Mean asymptotic SE	Coverage rate (%)	
Longitudinal submodel										
Intercept	β_0	142	140.8	0.808	0.667	52.67	140.8	0.791	0.701	56.67
Slope	β_1	0.7	3.129	0.208	0.190	0	3.135	0.202	0.192	0
Variability	μ_0	2.4	2.406	0.024	0.023	94.00	2.403	0.023	0.024	95.67
	μ_1	0.05	0.052	0.011	0.011	92.00	0.052	0.011	0.011	93.00
Σ_b	$\sigma_{b_0}^2$	210.25	201.1	18.24	14.41	78.33	200.9	17.80	15.48	81.67
	$\sigma_{b_0b_1}$	-17.4	-5.874	3.567	2.986	8.33	-6.096	3.308	3.097	8.67
Σ_τ	$\sigma_{b_1}^2$	9.28	7.067	1.372	0.991	41.33	7.068	1.203	1.027	43.67
	$\sigma_{\tau_0}^2$	0.09	0.085	0.019	0.016	88.00	0.090	0.018	0.016	92.33
	$\sigma_{\tau_0\tau_1}$	-0.018	-0.016	0.007	0.006	86.67	-0.018	0.007	0.006	93.00
	$\sigma_{\tau_1}^2$	0.0136	0.012	0.003	0.003	83.67	0.014	0.003	0.003	92.00
Survival submodel 1										
Current variance	α_σ	0	-0.001	0.023	0.022	96.00	0.001	0.022	0.022	95.00
Current value	α_1	0.03	0.030	0.005	0.005	95.67	0.030	0.005	0.005	95.67
Weibull	$\sqrt{\kappa}$	1.1	1.108	0.041	0.040	94.00	1.108	0.041	0.040	94.00
	ζ_0	-7	-6.965	0.788	0.789	94.33	-6.966	0.786	0.787	94.33

SE : Standard Error ; Coverage rate : coverage rate of the 95% confidence interval.

* Results for 300 replicates with complete convergence over 300 for step 1 and step 2.

TABLE S7 – Parameter estimates of the CVCS joint model on the Progress clinical trial data.

Parameter	Estimate	Standard error	p-value
<i>Survival submodel for CVD</i>			
BP current value	0.003	0.003	0.318
BP current slope	-0.122	0.017	< 0.001
treatment group	-0.093	0.081	0.253
male	0.277	0.087	0.002
age	0.041	0.005	< 0.001
<i>Survival submodel for Death</i>			
BP current value	-0.005	0.007	0.487
BP current slope	-0.100	0.045	0.038
treatment group	-0.008	0.067	0.907
male	0.493	0.194	0.011
age	0.057	0.010	< 0.001
<i>Longitudinal submodel</i>			
<u>Blood Pressure Mean</u>			
intercept	142.7	0.345	< 0.001
time	-0.146	0.073	0.046
treatment group	-7.942	0.457	< 0.001

BP : Blood Pressure




FIGURE S1 – Survival submodel for CVD (top) and death (bottom) fit assessment : comparison between predicted cumulative hazard function (in purple) and Nelson Aalen estimator (in grey).




FIGURE S2 – Survival submodel for CVD (left) and death (right) fit assessment for Sex (top) and Randomization group (bottom) : comparison between predicted cumulative hazard function and Nelson Aalen estimator.